Objective To investigate the changes and clinical significance of serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) before and after chemotherapy or operation treatment in patients with lung cancer. Methods 600 cases of lung cancer patients were collected from departments of respiratory medicine and thoracic surgery. The blood lipid levels in patients with lung cancer before and after chemotherapy or operation treatment were analyzed and compared with that of the healthy controls. Results The serum levels of TC, LDL-C and HDL-C in patients with lung cancer were significantly decreased compared with control group, but there was no significant difference on serum TG levels. The levels of TC and LDL-C were significantly increased in patients with lung cancer after operation or chemotherapy, while there was no significantly changes on levels of the plasma TG and HDL-C. Conclusion The patients with lung cancer have a tendency of lower level of blood cholesterol, and the serum levels of TC and LDL-C may be improved after chemotherapy or operation treatment.
HUANG Ai-ben
,
PANG Li
,
JIANG Yan-wen
,
FANG Qiu-hong
,
MA Ying-min
. Changes of Serum Lipid Levels Before and After Chemotherapy or Operation in Patients with Lung Cancer[J]. Labeled Immunoassays and Clinical Medicine, 2013
, 20(2)
: 65
-68
.
DOI: 10.11748/bjmy.issn.1006-1703.2013.02.001
[1] Strasak A M, Pfeiffer R M, Bran L J,et al. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women:a prospective 19-year follow up study[J].Ann Oncol,2009, 20(6):1113-1120.
[2] Furberg A S, Veierd M B, Wilsgaard T,et al.Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk[J].J Natl Cancer Inst,2004, 96(15):1152-1160.
[3] Fiorenza A M, Branchi A, Sommariva D.Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects[J]. Int J Clin Lab Res, 2000, 30(3):141-145.
[4] Siemianowicz K, Gminski J, Stajszczyk M,et al. Serum total cholesterol and triglycerides levels in patients with lung cancer[J].Int J Mol Med, 2000, 5(2):201-205.
[5] Umeki S. Decreases in serum cholesterol levels in advanced lung cancer[J]. Respiration,1993, 60(3):178-181.
[6] Jafri H, Alsheikh-Ali A A, Karas R H. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy[J]. J Am Coll Cardiol,2010 ,55(25):2846-2854.
[7] Gürdal-Yüksel E, Karada M, Ozyardimci N, et al. Cigarette smoking, serum lipids, folate, and vitamin B12 in lung cancer[J]. J Environ Pathol Toxicol Oncol,1996, 15(2-4):161-167.
[8] Jacobs E J, Newton C C, Thun M J, et al. Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort[J]. Cancer Res,2011, 71:1763-1771.
[9] Dessi S, Batetta B, Pulisci D, et al.Altered pattern of lipid metabolism in patients with lung cancer[J]. Oncology,1992, 49(6):436-441.
[10] Furberg A S, Jasienska G, Bjurstam N, et al. Metabolic and hormonal profiles:HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA Study[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):33-40.
[11] Weinstein S J, Wright M E, Lawson K A, et al. Serum and dietary vitamin E in relation to prostate cancer risk[J]. Cancer Epidemiol Biomarkers Prev,2007, 16(6):1253-1259.
[12] Lavigne.Low LDL Cholesterol is Related to Cancer Risk[N].Science Daily, 2012-3-25.
[13] Barter P, Gotto A M, LaRosa J C, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events[J]. N Engl J Med, 2007,357(13):1301-1310.
[14] Mantovani A, Allavena P, Sica A,et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203):436-444.
[15] Rajput S, Wilber A. Roles of inflammation in cancer initiation, progression,and metastasis[J]. Front Biosci (Schol Ed),2010, 2:176-183.
[16] Alexopoulos C G, Pournaras S, Vaslamatzis M,et al.Changes in serum lipids and lipoproteins in cancer patients during chemotherapy[J].Cancer Chemother Pharmacol, 1992,30(5): 412-416.
